Review





Similar Products

99
Bruker Corporation maldi biotyper software version 2 0
Maldi Biotyper Software Version 2 0, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/maldi biotyper software version 2 0/product/Bruker Corporation
Average 99 stars, based on 1 article reviews
maldi biotyper software version 2 0 - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

99
Bio-Rad image lab software version 2 0 build 8 for pc
Image Lab Software Version 2 0 Build 8 For Pc, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/image lab software version 2 0 build 8 for pc/product/Bio-Rad
Average 99 stars, based on 1 article reviews
image lab software version 2 0 build 8 for pc - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

96
STATA Corporation r software version 4 2 2
R Software Version 4 2 2, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/r software version 4 2 2/product/STATA Corporation
Average 96 stars, based on 1 article reviews
r software version 4 2 2 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

99
Bio-Rad optical system software version 2 0
Optical System Software Version 2 0, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/optical system software version 2 0/product/Bio-Rad
Average 99 stars, based on 1 article reviews
optical system software version 2 0 - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

98
Bio-Rad cfx manager software version 2 0
a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.
Cfx Manager Software Version 2 0, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cfx manager software version 2 0/product/Bio-Rad
Average 98 stars, based on 1 article reviews
cfx manager software version 2 0 - by Bioz Stars, 2026-04
98/100 stars
  Buy from Supplier

99
Bio-Rad iq5 optical system software version 2 0
a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.
Iq5 Optical System Software Version 2 0, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/iq5 optical system software version 2 0/product/Bio-Rad
Average 99 stars, based on 1 article reviews
iq5 optical system software version 2 0 - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier

96
STATA Corporation comprehensive metaanalysis cma software version 2
a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.
Comprehensive Metaanalysis Cma Software Version 2, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/comprehensive metaanalysis cma software version 2/product/STATA Corporation
Average 96 stars, based on 1 article reviews
comprehensive metaanalysis cma software version 2 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

98
Bio-Rad bio rad cfx manager 2 0 version 2 0 885 0923 software
a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.
Bio Rad Cfx Manager 2 0 Version 2 0 885 0923 Software, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bio rad cfx manager 2 0 version 2 0 885 0923 software/product/Bio-Rad
Average 98 stars, based on 1 article reviews
bio rad cfx manager 2 0 version 2 0 885 0923 software - by Bioz Stars, 2026-04
98/100 stars
  Buy from Supplier

96
STATA Corporation epidata software version 2 2
a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.
Epidata Software Version 2 2, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/epidata software version 2 2/product/STATA Corporation
Average 96 stars, based on 1 article reviews
epidata software version 2 2 - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

Image Search Results


a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig.  . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.

Journal: Nature Communications

Article Title: Endoglin as a BMP9 co-receptor in vascular endothelial cells: prodomain displacement and TGFBRII recruitment

doi: 10.1038/s41467-025-67531-9

Figure Lengend Snippet: a Superposition of the ENG-OR:BMP9 (5HZW) structure with the TGF-β1:TGFBRII (3KFD) structure by the ligands, showing ENG and TGFBRII can contact BMP9 simultaneously without any clash. Figure prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0, Schrödinger). b Effects of type II receptor knockdown on Smad1 phosphorylation induced by BMP9 in human pulmonary arterial endothelial cells (HPAECs). Cells were serum-starved in EGM-2, 0.1% FBS overnight, and treated with BMP9 for 15 min before being harvested for immunoblotting against an anti-pSmad1 antibody. GAPDH was used as the loading control. N = 4 independent siRNA experiments using the HPAECs from two donors. The quantification of pSmad1 relative to siCP control is shown on the right. c RT-qPCR examining the efficiency of siRNA in ( b ) and expression of other type II receptors after siRNA treatment. For ( b and c ), means ± SEM are shown, one-way ANOVA with Dunnett’s post-tests to compare with siCP-treated samples, for each receptor ( c ). Only significant p -values (<0.05) are shown. d Schematic description of the ENG pull-down assay. NHS = N-Hydroxysuccinimide, here refers to the HiTrap NHS-activated high-performance column. e Unique p e ptide counts from the mass spectrometry of the ENG pull-down assay. Only selected target proteins and controls are shown. The sequences of the peptides are mapped onto the protein sequences, as shown in ( f ) for TGFBRII and Supplementary Fig. . g Immunoblots showing Smad1/5 phosphorylation status of the samples used in the mass spectrometry experiments. h Diagrams (generated using BioRender) summarising the components investigated and the protein-protein interactions identified in the pull-down/mass spectrometry experiments. HAOECs human aortic endothelial cells, HUVECs human umbilical vein endothelial cells.

Article Snippet: The cDNAs were analysed by qPCR, and calculations were performed using the CFX Manager software version 2.0 (Bio-Rad).

Techniques: Knockdown, Phospho-proteomics, Western Blot, Control, Quantitative RT-PCR, Expressing, Pull Down Assay, Mass Spectrometry, Generated, Protein-Protein interactions